Randomized, Double-blind, Placebo-controlled Study Assessing Safety and Tolerability of Laquinimod

Study Title

A Multinational, Randomized, Double-blind, ParFemale, Maleel-group, Placebo-controlled Study Assessing the Safety and Tolerability

Teva Identifier

LAQ-MS-201

ClinicalTrials.gov Identifier

NCT01404117

Study Status

Withdrawn

Trial Condition(s)

Relapsing Multiple Sclerosis

Interventions

Drug: Laquinimod 0.6 | Drug: Laquinimod 1.2 | Other: Glatiramer Acetate or interferon-beta+ Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria
neurology icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 55 Years

Trial Duration

03/01/2012 - 01/01/2014

Phase

Phase 2

Study Type

Interventional